COYA 303 is an investigational proprietary combination of LD-IL-2 and GLP-1RA for subcutaneous administration, under development for the treatment of diseases, including Alzheimer's Disease, driven by ...
More than two weeks after the U.S. Supreme Court’s June 30 ruling in 303 Creative v. Elenis – which held that the First Amendment allows owners of creative businesses to refuse service to same-sex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results